Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Up 9.2% in January

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) saw a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 18,900 shares, an increase of 9.2% from the January 15th total of 17,300 shares. Based on an average daily volume of 43,200 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.7% of the company’s shares are short sold.

Kiora Pharmaceuticals Stock Up 0.6 %

NASDAQ KPRX traded up $0.02 on Friday, hitting $3.62. 24,728 shares of the company were exchanged, compared to its average volume of 35,204. Kiora Pharmaceuticals has a 12 month low of $3.00 and a 12 month high of $6.75. The stock has a fifty day moving average of $3.59 and a 200-day moving average of $3.57.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Kiora Pharmaceuticals in a research note on Tuesday, November 12th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Kiora Pharmaceuticals stock. ADAR1 Capital Management LLC boosted its holdings in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) by 1.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 200,221 shares of the company’s stock after buying an additional 3,670 shares during the period. ADAR1 Capital Management LLC owned approximately 6.67% of Kiora Pharmaceuticals worth $661,000 as of its most recent SEC filing. Institutional investors own 76.97% of the company’s stock.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.